Head For a Cure 5K to Benefit Hermelin Brain Tumor Center

September 04, 2014

DETROIT – The Head For a Cure 5K fundraiser benefitting the Hermelin Brain Tumor Center at Henry Ford Hospital and the Head for a Cure Foundation takes place at the Detroit Riverfront at 8 a.m. Saturday, Sept. 6.

Funds raised through the Head for the Cure Foundation provided the seed money to help launch the Brain Tumor Trials Collaborative, a network of highly respected and dedicated doctors at renowned medical centers across the nation including the Hermelin Brain Tumor Center.

The collaborative has grown to more than 23 member institutions and has experienced unparalleled advancements in the research of alternative treatments of malignant brain tumors. Research studies are being conducted to make promising advances into cancer prevention, diagnosis and treatments that are safe and effective.

Race Day schedule:

  • 7 a.m.: Late Packet Pick Up and Check In
  • 8 a.m.: Head for the Cure 5K - Detroit starts (walk starts 5 minutes after run start)
  • 9:15 a.m.: Head for the Cure Kids Run
  • 5k Race Awards: Immediately following 5k

The venue is located at 100 Talon Centre Drive, at the intersection of Joseph Campau and River Place Drive.

To register for the event, go to http://www.headforthecure.org/troidet. Online registration closes at 5 p.m., Sept. 4, 2014.

About Hermelin Brain Tumor Center
The Hermelin Brain Tumor Center has been the leader in brain tumor research and treatment in Michigan for the past 20 years. Among the top centers in the U.S., the Center treats 750 new brain tumor patients (and provides 2,750 Brain Tumor Board evaluations annually). In total the Center conducts 7,800 brain tumor patient visits annually. The Center was a founding member and one of only 12 nationally of the NIH-sponsored Adult Brain Tumor Consortium. As one of the top three largest brain tumor banks globally, the Hermelin Center was one of the largest contributors to The Cancer Genome Atlas. The Center also offers intraoperative MRI for more complete tumor resection and clinical trials not available for adults elsewhere in the state.